i&E Magazine Summer 2010

Page 1

Summer 2010

PATHWAY TO

SUCCESS Selexys Pharmaceuticals targets inflammatory disease with Oklahoma-developed drugs

RURAL ROOTS

Durant-based REI takes economic development mission statewide

CAPITAL MILESTONE

Historic proof-of-concept funding awarded to water remediation business

GOVERNOR’S CUP ROADMAP Pointing college students in the right direction

The Selexys Pharmaceuticals management trio of (from left), David Falconer, vice president of business and development; Scott Rollins, chief executive officer; and Rick Alvarez, vice president of operations and research, have the Oklahoma City company on track to begin human clinical trials by early 2011 for drugs to treat Sickle Cell and Crohn’s diseases.


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.